pimecrolimus: prescribing and clinical use
Focused clinical detail for use alongside current product information, local policy and patient-specific assessment.
pimecrolimus: clinical details
Prescribing considerations
- Initiation should be by a clinician experienced in diagnosing and treating atopic dermatitis.
- Confirm mild or moderate atopic dermatitis and why topical corticosteroids are inadvisable or not possible.
- Clear clinical infection at treatment sites before starting; discontinue at sites affected by herpes simplex until resolved.
- Avoid potentially malignant or premalignant lesions, acute viral skin infection and occlusion.
- Do not use in congenital or acquired immunodeficiency or during immunosuppressive treatment.
- Pimecrolimus is not recommended in Netherton syndrome; safety is not established in erythroderma.
- Advise sun protection and avoidance of therapeutic or artificial ultraviolet exposure.
- Severely inflamed or damaged skin may increase systemic exposure.
Contraindications and cautions
- Hypersensitivity to pimecrolimus, other macrolactams or any excipient
Monitoring
- Reassess if eczema worsens or does not improve.
- Assess new infection, particularly herpes simplex, eczema herpeticum or impetigo.
- Investigate lymphadenopathy and monitor until it resolves; discontinue if no cause is found or infectious mononucleosis is present.
- Reassess the benefit–risk balance after a severe application-site reaction.
Clinical pharmacology
Pimecrolimus is a lipophilic ascomycin macrolactam derivative. By binding macrophilin-12 and inhibiting calcineurin, it suppresses T-cell inflammatory cytokine synthesis. Skin permeation and systemic absorption are generally very low.
Formulation and product differences
- The selected product is a whitish, homogeneous cream for cutaneous use.
- Cetyl alcohol and stearyl alcohol may cause local skin reactions; benzyl alcohol may cause allergy or mild irritation, and propylene glycol may irritate skin.
- Cream transferred to clothing, bedding or dressings can increase fabric flammability.
pimecrolimus preparations and strengths
Cream
Route: Cutaneous
Strengths: 10 mg/g
pimecrolimus interactions
Systemic medicine interactions are considered unlikely because skin absorption is minimal, but several treatment-related precautions apply.
UVA, UVB or PUVA treatment
Avoid combining with pimecrolimus because concurrent use has not been adequately studied and excessive ultraviolet exposure should be avoided.
Systemic immunosuppressants such as azathioprine or ciclosporin
Concurrent treatment for eczema is not supported by clinical experience and should be avoided unless directed by a specialist.
Vaccinations
Do not apply pimecrolimus to a vaccination site while a local reaction remains; vaccination timing may need review in extensive eczema.
Sources
These sources were used to prepare and review this medicine page.
Prepared and reviewed by the iatroX editorial team.